SLC5A2 and diabetes mellitus: No significant association was found for sodium glucose cotransporter-2 inhibitors (SGLT-2is) [65]. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, it was shown that PCa was present in DM patients at a lower proportion among liraglutide users, as compared to the placebo group [66].